Overview
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1) developed by Novo Nordisk. It shares approximately 94% sequence homology with native GLP-1 but incorporates structural modifications — including a C-18 fatty acid chain attached via a linker — that enable albumin binding and dramatically extend its half-life to approximately 7 days, allowing once-weekly subcutaneous injection or daily oral dosing. Semaglutide is one of the most extensively studied peptide compounds in clinical medicine, with large-scale Phase III trials including SUSTAIN (diabetes), STEP (obesity), SELECT (cardiovascular outcomes), and SOUL (renal outcomes). It is approved by the FDA for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with obesity.
Mechanism
Semaglutide acts as a full agonist at the GLP-1 receptor, which is expressed in pancreatic beta cells, the central nervous system (hypothalamus, brainstem), the gastrointestinal tract, and cardiac tissue. Key mechanisms include: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression via hypothalamic GLP-1 receptors. The weight loss effect is primarily mediated centrally rather than through peripheral GI effects alone.
Research Areas
Side Effects (Preclinical)
- – Nausea and vomiting (most common, especially on dose escalation)
- – Diarrhea and constipation
- – Injection-site reactions
- – Rare: pancreatitis, gallbladder disease
- – Rare: thyroid C-cell tumors (observed in rodent studies; clinical relevance unclear)
Cautions
- – Approved pharmaceutical drug — research-grade semaglutide is distinct from pharmaceutical products
- – Contraindicated (per labeling) in personal/family history of medullary thyroid carcinoma
- – Risk of hypoglycemia when combined with insulin or sulfonylureas
- – Research-grade material: not subject to pharmaceutical quality controls; intended for laboratory research only
Menopause & Women's Health Relevance
Weight gain at perimenopause is driven by a combination of estrogen decline, increased insulin resistance, and reduced resting metabolic rate — the exact targets of GLP-1 receptor agonism. The STEP 1 trial was approximately 75% female and demonstrated 14.9% mean body weight reduction. Emerging research is investigating GLP-1 agonists specifically in the perimenopausal and post-menopausal metabolic context.
What the research shows
Semaglutide has the most extensive clinical evidence base of any compound in the peptide research space. The STEP 1 trial (Wilding et al., 2021) demonstrated mean body weight reduction of 14.9% over 68 weeks in adults with obesity. The SELECT cardiovascular outcomes trial (Lincoff et al., 2023) showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease.
Important note on research-grade vs. pharmaceutical: Research-grade semaglutide sold by peptide vendors is not FDA-approved pharmaceutical product. It is intended for laboratory and in-vitro research only.
References
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — Lincoff AM et al. (2023)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — Wilding JPH et al. (2021)